Immunic Announced The Outcome Of The Non-binding, Interim Futility Analysis Of Its Phase 3 ENSURE Program Of Vidofludimus Calcium (IMU-838), For Relapsing Multiple Sclerosis, An Unblinded Independent Data Monitoring Committee Has Recommended That The Trials Are Not Futile And Should Continue As Planned
Portfolio Pulse from Benzinga Newsdesk
Immunic announced that an independent committee recommended the continuation of its Phase 3 ENSURE trials for Vidofludimus Calcium (IMU-838) in treating relapsing multiple sclerosis, indicating the trials are not futile. ENSURE-1 is expected to complete in Q2 2026 and ENSURE-2 in H2 2026.
October 22, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunic's Phase 3 ENSURE trials for Vidofludimus Calcium in relapsing multiple sclerosis are recommended to continue by an independent committee, suggesting positive progress.
The recommendation to continue the trials suggests that the data so far is promising, which is a positive indicator for the future success of the drug. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90